Phio to Host May 19 Fireside Chat as PH-762 Delivers 65% Response Rate
PHIO•Phio’s Phase 1b trial of PH-762 in skin cancers treated 22 patients across five dose cohorts with no dose-limiting toxicities and achieved a 65% pathological response rate overall and 85% at the highest dose. The company plans FDA engagement in Q2 2026 and maintains cash runway into H1 2027.
1. Phase 1b Trial Results
Phio’s lead candidate PH-762 was evaluated in a Phase 1b trial for cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. Across five dose-escalation cohorts, 22 patients completed treatment with no dose-limiting toxicities; the trial reported a 65% pathological response rate overall and an 85% response in the highest-dose cohort.
2. Fireside Chat and Development Outlook
Phio will host a virtual fireside chat on May 19 at 4 PM EDT featuring CEO Robert Bitterman, Force Family Office CEO Steven Saltzstein and dermatologist Mary Spellman to discuss INTASYL’s skin cancer prevention and treatment innovations. The company targets FDA engagement in Q2 2026 for next-stage clinical planning and holds cash to fund operations into the first half of 2027.
